Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist — approved as Mounjaro for type 2 diabetes and Zepbound for obesity. Clinical trials show 20–22% average body weight reduction, making it the most effective approved pharmacological weight loss treatment available.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Tirzepatide was developed by Eli Lilly and received FDA approval in 2022 (Mounjaro, T2D) and 2023 (Zepbound, obesity). It is the first approved "twincretin" — a single molecule that activates both the GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. The dual mechanism produces greater metabolic effects than GLP-1 agonism alone, including more significant weight loss, better glycemic control, and favorable effects on cardiovascular risk factors. SURMOUNT-1 Phase 3 data showed 22.5% average body weight reduction at the highest dose — results historically only achievable with bariatric surgery.
Mechanism of Action
Tirzepatide acts on two incretin receptors. At GLP-1 receptors: it delays gastric emptying, suppresses appetite via vagal and CNS pathways, stimulates glucose-dependent insulin secretion, and reduces glucagon. At GIP receptors: it enhances insulin secretion, promotes adipose tissue lipid metabolism, and appears to improve insulin sensitivity and energy expenditure in ways GLP-1 agonists alone cannot. GIP receptor agonism in adipose tissue also seems to reduce the GI side effects associated with pure GLP-1 agonists, improving tolerability. Together, the two receptor pathways produce greater CNS satiety signaling, better glucose disposal, and more favorable body composition changes (greater fat loss, better lean mass preservation relative to body weight lost).
Key Research
SURPASS trials (Phase 3, T2D): tirzepatide 10–15 mg outperformed both semaglutide 1 mg and insulin degludec on HbA1c reduction. SURMOUNT-1 (Phase 3, obesity, N=2,539): 22.5% average weight reduction at 72 weeks with 15 mg — 56% of participants achieved ≥20% weight loss. SURMOUNT-MMT showed 18.4% reduction in people with sleep apnea. CVD outcomes trial (SURMOUNT-4) demonstrates maintained weight loss with continued therapy. FDA approved for obesity (Zepbound) in November 2023. The cardiovascular outcomes data (SURPASS-CVOT) is pending.
Tirzepatide is escalated gradually: 2.5 mg weekly for 4 weeks, then increasing by 2.5 mg every 4 weeks to the maintenance dose (5 mg, 10 mg, or 15 mg). Slower escalation is recommended if GI side effects are significant. Injected subcutaneously (abdomen, thigh, or upper arm) once weekly on the same day each week. As a pharmaceutical, it is dispensed in pre-filled autoinjector pens. Research and off-label use follows the same titration protocol.
Obesity Research Protocol: titrate from 2.5 mg weekly to 15 mg weekly over 20–24 weeks, maintain at 10–15 mg for duration of study. Can be combined with cagrilintide (CagriSema-equivalent) in advanced combination protocols for potentially additive satiety pathways. Metabolic Syndrome Protocol: tirzepatide 5–10 mg weekly alongside MOTS-c for complementary visceral fat and insulin resistance targeting.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
GI side effects are the most common: nausea (44%), diarrhea (23%), vomiting (18%), and constipation (17%) in SURMOUNT-1, predominantly during dose escalation and typically manageable. Slow titration significantly reduces their severity. Gallbladder disease and cholelithiasis are reported at higher rates than placebo, consistent with rapid weight loss. Injection site reactions are mild and transient. Hypoglycemia risk is low without concurrent insulin or sulfonylurea use. Pancreatitis risk is listed as a concern per class effect but no causal relationship has been established in RCTs. Thyroid C-cell tumor risk (from rodent data) carries a black-box warning — contraindicated in personal or family history of medullary thyroid carcinoma.
Storage & Handling
Pre-filled pens store at 2–8°C. Protect from light — store in original carton. May be stored at room temperature (up to 30°C) for up to 21 days if removed from refrigeration. Do not freeze. Do not use if solution is discolored or contains visible particles. Store away from heat sources; do not leave in a hot vehicle.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
